Peter McAllister, MD,

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

Obesity medicine expert Caissa Troutman, MD, suggests using annual physicals as a "gateway" to identify patients with obesity with elevated blood pressure.

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.

Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.

If approved, neffy 1 mg will be the only needle-free epinephrine treatment available for the younger, school-aged population.

Your daily dose of the clinical news you may have missed.

Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.

An FDA decision on GSK's Shingrix application is expected by June 20, 2025.

The study will assess the safety, tolerability, and pharmacokinetics of PMN310 in individuals with mild cognitive impairment or early-stage AD.

Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.

The acquisition brings lumateperone, known as Caplyta, and the clinical-stage agent ITI-1284, for generalized anxiety disorder and Alzheimer's agitation, into the J&J fold.

The Los Angeles wildfires continue nearly unabated despite heroic efforts by first responders. Wildfire smoke has both short- and long-term effects on health and habitat. Here's what to know, for you and your patients.

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Your daily dose of the clinical news you may have missed.

The planned Phase 2 trial in IPF will focus on assessing MTX-463’s safety, pharmacokinetics, and efficacy.

Caissa Troutman, MD, an obesity medicine and family medicine physician, emphasizes early treatment of obesity, along with HTN management, can improve patient outcomes.

Treatments with the investigational rescue medication achieved clinically effective epinephrine levels faster than intramuscular injection.

An earlier phase 2 study found statistically significant improvement of MDD in female participants.